BDRX vs IMCC
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a critically weak financial profile with a Piotroski F-Score of 2/9, indicating severe operational and financial distress. Despite a strong current and quick ratio suggesting short-term liquidity, the company is unprofitable across all margins, with deeply negative ROE and ROA. Valuation metrics are largely undefined due to lack of earnings and revenue data, while the stock has lost nearly all value over the past year. Insider sentiment is neutral-to-weak, and there is no analyst coverage or dividend support, amplifying risk.
IMCC exhibits severe financial distress, characterized by a Piotroski F-Score of 4/9 and the absence of a Graham Number or Altman Z-Score due to negative equity (Price/Book: -0.80). While the company has shown recent revenue growth of 17.6% and a series of EPS 'beats,' these are marginal improvements on a foundation of deep losses and negative margins. The catastrophic 5-year price decline of 99.9% and a current ratio of 0.67 indicate a high risk of insolvency and a lack of investor confidence.
Compare Another Pair
Related Comparisons
BDRX vs IMCC: Head-to-Head Comparison
This page compares Biodexa Pharmaceuticals Plc (BDRX) and IM Cannabis Corp. (IMCC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.